Success Metrics

Clinical Success Rate
84.4%

Based on 27 completed trials

Completion Rate
84%(27/32)
Active Trials
7(13%)
Results Posted
26%(7 trials)
Terminated
5(9%)

Phase Distribution

Ph phase_1
2
4%
Ph phase_2
3
5%
Ph phase_4
25
45%
Ph early_phase_1
1
2%
Ph not_applicable
7
13%
Ph phase_3
9
16%

Phase Distribution

3

Early Stage

3

Mid Stage

34

Late Stage

Phase Distribution47 total trials
Early Phase 1First-in-human
1(2.1%)
Phase 1Safety & dosage
2(4.3%)
Phase 2Efficacy & side effects
3(6.4%)
Phase 3Large-scale testing
9(19.1%)
Phase 4Post-market surveillance
25(53.2%)
N/ANon-phased studies
7(14.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

27 of 36 finished

Non-Completion Rate

25.0%

9 ended early

Currently Active

7

trials recruiting

Total Trials

55

all time

Status Distribution
Active(10)
Completed(27)
Terminated(9)
Other(9)

Detailed Status

Completed27
unknown9
Recruiting6
Terminated5
Withdrawn4
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
55
Active
7
Success Rate
84.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.1%)
Phase 12 (4.3%)
Phase 23 (6.4%)
Phase 39 (19.1%)
Phase 425 (53.2%)
N/A7 (14.9%)

Trials by Status

enrolling_by_invitation12%
recruiting611%
completed2749%
withdrawn47%
not_yet_recruiting24%
terminated59%
unknown916%
active_not_recruiting12%

Recent Activity

Clinical Trials (55)

Showing 20 of 55 trialsScroll for more
NCT05741502Phase 4

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

Terminated
NCT04580134Phase 4

CLOZAPINE Response in Biotype-1

Recruiting
NCT05208190Phase 4

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

Recruiting
NCT05603104Phase 3

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting
NCT05316883Phase 4

Biomarkers in Clozapine-responding Schizophrenia

Recruiting
NCT07262736Phase 1

Pharmacokinetics of Clozapine and Norclozapine and the Effect of Pantoprazole

Completed
NCT05958875Phase 4

The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting
NCT07085195Early Phase 1

A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease

Not Yet Recruiting
NCT06969755Phase 4

Biomarkers to Enhance Early Schizophrenia Treatment

Not Yet Recruiting
NCT02640300Phase 4

Switching Antipsychotics: Abrupt Discontinuation Versus Overlap

Completed
NCT04529226Phase 2

Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis

Active Not Recruiting
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT06159322

Characterizing Response to Antipsychotics in Schizophrenia

Unknown
NCT02639702Phase 4

Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia

Recruiting
NCT06011460

Observation of Clozapine Treatment Safety in Bipolar Disorder.

Enrolling By Invitation
NCT02404155Not Applicable

Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)

Completed
NCT02714894

Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study

Unknown
NCT01498770

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

Completed
NCT03772951Phase 4

The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia

Completed
NCT02286206Phase 4

Study of the Effect of Dosing on Clozapine Levels

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
55